Literature DB >> 17235654

Surgical outcomes and risk factors for postoperative complications in patients with Behcet's disease.

Min-Chan Park1, Bum-Kee Hong, Hyuck Moon Kwon, You-Sun Hong.   

Abstract

This study aims to investigate surgical outcomes in patients with Behcet's disease (BD) and to identify risk factors for the occurrence of postoperative complications. The medical records of 37 patients with newly diagnosed BD were reviewed retrospectively. All patients fulfilled the International Study Group criteria for diagnosis of BD and underwent surgeries after diagnosis. Demographic, clinical, and laboratory data at the time when surgeries were performed were collected and surgical modalities, postoperative complications, and postoperative medical treatments were evaluated. Forty-three surgeries were performed in 37 patients. During mean follow-up duration of 78.2 +/- 50.3 months, 14 surgeries (32.6%) were complicated by wound dehiscence, infection, and graft occlusion or failure with the mean lag time of 6.0 +/- 4.6 months from surgeries. Cumulative incidence of postoperative complications was 7.7% at 3 months, 25.6% at 6 months, 33.3% at 12 months, and 35.9% at 18 months. Postoperative complications occurred more frequently after surgeries that were performed in patients with positive pathergy test (P < 0.001) and after vascular surgeries than after nonvascular surgeries (P < 0.05). Moreover, surgeries that were followed by glucocorticoids with immunosuppressive agents showed a significantly lower postoperative complication rate compared to those that were followed by glucocorticoids alone and those that were not followed by medical treatment (P < 0.05). Multivariate analysis showed that a positive pathergic reaction (P < 0.05, hazard ratio = 1.91) at the time of surgery and surgeries that were not followed by treatment with glucocorticoids and immunosuppressive agent (P < 0.01, hazard ratio = 2.11) was an independent risk factor for the occurrence of postoperative complications. Our findings suggest that the occurrence of postoperative complications can be reduced when postsurgical immunosuppressive treatment was implemented and that the pathergy test can be used as screening methods for occurrence of postoperative complications in patients with BD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17235654     DOI: 10.1007/s10067-006-0530-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

Review 1.  Behçet's disease and cardiovascular involvement.

Authors:  F Atzeni; P Sarzi-Puttini; A Doria; L Boiardi; N Pipitone; C Salvarani
Journal:  Lupus       Date:  2005       Impact factor: 2.911

2.  Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease.

Authors:  J L Jorizzo; W L White; C M Wise; M D Zanolli; E F Sherertz
Journal:  J Am Acad Dermatol       Date:  1991-06       Impact factor: 11.527

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 4.  Vasculitis in Behçet's disease.

Authors:  J D O'Duffy
Journal:  Rheum Dis Clin North Am       Date:  1990-05       Impact factor: 2.670

5.  Gastrointestinal involvement in Behçet's syndrome: a controlled study.

Authors:  S Yurdakul; N Tüzüner; I Yurdakul; V Hamuryudan; H Yazici
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

6.  Surgical treatment of Behçet's disease involving aortic regurgitation.

Authors:  M Ando; Y Kosakai; Y Okita; K Nakano; S Kitamura
Journal:  Ann Thorac Surg       Date:  1999-12       Impact factor: 4.330

7.  Behçet's syndrome. Immunopathologic and histopathologic assessment of pathergy lesions is useful in diagnosis and follow-up.

Authors:  J L Jorizzo; A R Solomon; T Cavallo
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

8.  Compelling nature of arterial manifestations in Behcet disease.

Authors:  Zafer H Iscan; Kerem M Vural; Murat Bayazit
Journal:  J Vasc Surg       Date:  2005-01       Impact factor: 4.268

9.  Arterial lesions in Behçet's disease. A study in 25 patients.

Authors:  D Lê Thi Huong; B Wechsler; T Papo; J C Piette; O Bletry; J M Vitoux; E Kieffer; P Godeau
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

10.  Characteristics of vascular involvement in Behçet's disease.

Authors:  N Düzgün; A Ateş; O T Aydintuğ; O Demir; U Olmez
Journal:  Scand J Rheumatol       Date:  2006 Jan-Feb       Impact factor: 3.641

View more
  5 in total

1.  Budd-Chiari Syndrome in Behçet's Disease successfully managed with immunosuppressive and anticoagulant therapy: A case report and literature review.

Authors:  Christian Mario Amodeo Oblitas; Francisco Galeano-Valle; Neera Toledo-Samaniego; Blanca Pinilla-Llorente; Jorge Del Toro-Cervera; Arturo Álvarez-Luque; Alejandra García-García; Pablo Demelo-Rodriguez
Journal:  Intractable Rare Dis Res       Date:  2019-02

2.  Intracardiac thrombosis in Behçet's Disease successfully treated with immunosuppressive agents: A case of vascular pathergy phenomenon.

Authors:  Francisco Galeano-Valle; Pablo Demelo-Rodriguez; Luís Álvarez-Sala-Walther; Blanca Pinilla-Llorente; Miguel Jesús Echenagusia-Boyra; Hugo Rodriguez-Abella; Jorge Del-Toro-Cervera
Journal:  Intractable Rare Dis Res       Date:  2018-02

Review 3.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

Review 4.  Experimental Therapeutic Solutions for Behcet's Disease.

Authors:  Burçin Cansu Bozca; Erkan Alpsoy
Journal:  J Exp Pharmacol       Date:  2021-02-12

5.  Perioperative management with biologics on severe aortic valve regurgitation caused by Behçet syndrome: the experience from a single center.

Authors:  Luxi Sun; Jinjing Liu; Xiufeng Jin; Zhimian Wang; Lu Li; Wei Bai; Yunjiao Yang; Chanyuan Wu; Wei Chen; Shangdong Xu; Jun Zheng; Wenjie Zheng
Journal:  Ther Adv Chronic Dis       Date:  2021-06-22       Impact factor: 5.091

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.